15 citations
,
May 1966 in “The Journal of Urology” This case report discusses an instance of cystitis caused by the chemotherapy drug Cytoxan, with no new findings reported.
45 citations
,
July 2002 in “The Neurologist” This article reviews the challenges of using disease-modifying therapy for multiple sclerosis and offers strategies to improve treatment adherence and manage adverse effects, but reports no new clinical findings.
2 citations
,
January 1998 in “Neurourology and Urodynamics” This report describes a case of adrenomyeloneuropathy where serial urodynamic studies revealed neurogenic bladder dysfunction linked to demyelinating lesions in the patient.
17 citations
,
January 1998 in “Neurourology and Urodynamics” This report describes a case of adrenomyeloneuropathy where neurogenic bladder dysfunction developed, attributed to demyelinating lesions in the patient's peripheral nerves, spinal cord, and cerebral white matter.
August 2023 in “Journal of Education Health and Sport” This study reviewed information from various sources to highlight the versatile uses of botulinum toxin beyond aesthetic treatments, noting its successful application in fields like neurology, urology, and psychiatry, while also emphasizing its off-label therapeutic potential.
September 2022 in “Zenodo (CERN European Organization for Nuclear Research)” This article discusses Fluxactive Complete, a natural supplement for prostate health, and reports no new clinical results.
January 2025 in “Genetics in Medicine Open” This case report highlights a 33-year-old male initially misdiagnosed with Neuromyelitis Optica, whose symptoms may improve with biotin treatment due to late onset biotinidase deficiency.
1 citations
,
May 2008 in “Toxicon” This study found that BOTOX doses of 75–100 U effectively reduce postvoiding residual urine and detrusor pressure in patients with detrusor sphincter dyssynergia.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” This review discusses the therapeutic potential of potassium channel openers for various conditions, but notes that their clinical role is not yet fully established.
15 citations
,
August 2022 in “The Application of Clinical Genetics” This review describes the clinical presentation, diagnosis, and management of adrenomyeloneuropathy, including rehabilitative therapies and spasticity management, and reports no new clinical results.
January 2009 in “Side effects of drugs annual” This study observed no teratogenic effects of oral decongestants and surprisingly favorable neonatal outcomes in Swedish women who used them during pregnancy.
119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.
April 2025 in “Revista de Ciências da Saúde Nova Esperança” This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.
1 citations
,
June 2025 in “Pharmacia” This study highlights the growing use of botulinum toxin in both medical and cosmetic fields, showing its benefits and risks. Proper administration is crucial to avoid severe side effects like muscle weakness and respiratory issues, emphasizing the need for enhanced safety measures and regulations.
9 citations
,
July 2024 in “Toxins” This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.
September 1983 in “Journal of The American Academy of Dermatology” Experts discussed hair care, genetic hair defects, hair loss treatments, nail surgery, lupus treatments, skin infections, and cosmetic allergies.
51 citations
,
October 2002 in “British Journal of Dermatology” Finasteride increases hair density in female androgenetic alopecia, but individual results may vary.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.
19 citations
,
July 2018 in “Medicines” This review highlights the pharmaceutical potential of secondary metabolites from Juniperus species, noting promising antitumor, antibacterial, and antiviral activities, but reports no new experimental findings.
January 1982 in “Clin-Alert” Some medications caused temporary health issues that improved after stopping the drugs, but two patients died from liver problems linked to carbamazepine.
9 citations
,
April 2006 in “Experimental and Clinical Endocrinology & Diabetes” This article presents a case of primary adrenal localization of non-Hodgkin's lymphoma in a 70-year-old woman, detailing her diagnosis and treatment, with no signs of recurrent disease after polychemotherapy and radiotherapy.
March 2024 in “Romanian Medical Journal” This case report describes a 43-year-old woman with achalasia, pangastritis, and hyperthyroidism, highlighting the rare association between achalasia and autoimmune conditions like hyperthyroidism.
183 citations
,
January 1987 in “British Journal of Anaesthesia” This article discusses the long-standing use and safety of opioids in anaesthesia, noting that respiratory depression is a manageable side effect due to the availability of opioid antagonists.
86 citations
,
July 1990 in “British Journal of Pharmacology” Diazoxide, minoxidil sulphate, and cromakalim relax rat blood vessels by opening K+ channels, with some differences in their actions.
67 citations
,
February 2015 in “Life Sciences” This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.
60 citations
,
January 1989 in “Toxicologic Pathology” This paper discusses the pathogenesis of cardiovascular lesions in dogs associated with minoxidil, noting that lesions were not prevented by adrenergic blockade or neural activity suppression, and highlights the differences in injury progression between coronary arteries and the right atrium.
54 citations
,
October 2019 in “Cochrane library” This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.
44 citations
,
October 2017 in “British Journal of Dermatology” This review discusses the broadening scope of botulinum toxin applications beyond traditional uses, highlighting its effects on non-neuronal cells and potential in treating various dermatological conditions, without reporting new clinical findings.
40 citations
,
November 2016 in “Molecules” This review discusses the historical and current use of ribosome-inactivating protein-expressing plants in traditional medicine across various cultures and regions, highlighting their role despite a lack of scientific validation.
33 citations
,
May 1991 in “British Journal of Pharmacology” Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.